

LONBERG NILS  
Form 4  
September 03, 2009

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
LONBERG NILS

(Last) (First) (Middle)  
MEDAREX, INC., 521  
COTTONWOOD DRIVE  
(Street)

MILPITAS, CA 95035

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
MEDAREX INC [MEDX]

3. Date of Earliest Transaction  
(Month/Day/Year)  
09/01/2009

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
Sr. VP, Scientific Director

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  |                                | (A) or (D)  | Code V Amount (D) Price   |  |                                   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security | 2. Conversion or Exercise | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any | 4. Transaction Code | 5. Number of Derivative Securities | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|---------------------------------|---------------------------|--------------------------------------|-----------------------------------|---------------------|------------------------------------|--|---|
|---------------------------------|---------------------------|--------------------------------------|-----------------------------------|---------------------|------------------------------------|--|---|

Edgar Filing: LONBERG NILS - Form 4

| (Instr. 3)                  | Price of Derivative Security | (Month/Day/Year) | (Instr. 8) | Acquired (A) or Disposed of (D)<br>(Instr. 3, 4, and 5) |           | Date Exercisable | Expiration Date | Title        | Amount Number Shares |
|-----------------------------|------------------------------|------------------|------------|---|-----------|------------------|-----------------|--------------|----------------------|
|                             |                              |                  |            | Code  | V (A) (D) |                  |                 |              |                      |
| stock option (right to buy) | \$ 7.16                      | 09/01/2009       | D          |   | 13,976    | <u>(1)</u>       | 10/13/2013      | Common Stock | 13,976               |
| stock option (right to buy) | \$ 5.61                      | 09/01/2009       | D          |   | 17,842    | <u>(2)</u>       | 07/25/2014      | Common Stock | 17,842               |
| stock option (right to buy) | \$ 9.9                       | 09/01/2009       | D          |   | 10,101    | <u>(3)</u>       | 09/05/2015      | Common Stock | 10,101               |
| stock option (right to buy) | \$ 3.43                      | 09/01/2009       | D          |   | 169,152   | <u>(4)</u>       | 10/31/2009      | Common Stock | 169,14               |
| stock option (right to buy) | \$ 3.43                      | 09/01/2009       | D          |   | 54,848    | <u>(5)</u>       | 05/17/2010      | Common Stock | 54,848               |
| stock option (right to buy) | \$ 14.89                     | 09/01/2009       | D          |   | 100,000   | <u>(6)</u>       | 09/18/2011      | Common Stock | 100,00               |
| stock option (right to buy) | \$ 8.11                      | 09/01/2009       | D          |   | 200,000   | <u>(7)</u>       | 07/10/2012      | Common Stock | 200,00               |
| stock option (right to buy) | \$ 6.33                      | 09/01/2009       | D          |   | 25,000    | <u>(8)</u>       | 09/07/2013      | Common Stock | 25,000               |
| stock option (right to buy) | \$ 7.16                      | 09/01/2009       | D          |   | 186,024   | <u>(9)</u>       | 10/13/2013      | Common Stock | 186,02               |
| stock option (right to buy) | \$ 5.61                      | 09/01/2009       | D          |   | 167,158   | <u>(10)</u>      | 07/25/2014      | Common Stock | 167,15               |

buy)

stock

option  
(right to  
buy)

\$ 9.9

09/01/2009

D

239,899

(11)

09/05/2015

Common  
Stock

239,89

stock

option  
(right to  
buy)

\$ 14.92

09/01/2009

D

150,000

(12)

05/16/2017

Common  
Stock

150,00

stock

option  
(right to  
buy)

\$ 9.07

09/01/2009

D

129,000

(13)

03/02/2018

Common  
Stock

129,00

stock

option  
(right to  
buy)

\$ 3.72

09/01/2009

D

129,000

(14)

03/04/2019

Common  
Stock

129,00

Restricted  
Stock  
Units(15)

09/01/2009

D

14,119

(16)(17)Common  
Stock

14,119

Restricted  
Stock  
Units(15)

09/01/2009

D

43,000

(18)(19)Common  
Stock

43,000

Restricted  
Stock  
Units(15)

09/01/2009

D

43,000

(20)(21)Common  
Stock

43,000

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |                                   |       |
|---|---------------|-----------|-----------------------------------|-------|
|   | Director      | 10% Owner | Officer                           | Other |
| LONBERG NILS<br>MEDAREX, INC.<br>521 COTTONWOOD DRIVE<br>MILPITAS, CA 95035 |               |           | Sr. VP,<br>Scientific<br>Director |       |

## Signatures

NILS

LONBERG

04/06/2009

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option was canceled in the merger in exchange for a cash payment of \$123,617.72, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (2) This option was canceled in the merger in exchange for a cash payment of \$185,467.59, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (3) This option was canceled in the merger in exchange for a cash payment of \$61,616.10, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (4) This option was canceled in the merger in exchange for a cash payment of \$2,126,240.60, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (5) This option was canceled in the merger in exchange for a cash payment of \$689,439.36, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (6) This option was canceled in the merger in exchange for a cash payment of \$111,000, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (7) This option was canceled in the merger in exchange for a cash payment of \$1,578,000, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (8) This option was canceled in the merger in exchange for a cash payment of \$241,750.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (9) This option was canceled in the merger in exchange for a cash payment of \$1,645,382.28, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (10) This option was canceled in the merger in exchange for a cash payment of \$1,737,607.41, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (11) This option was canceled in the merger in exchange for a cash payment of \$1,463,383.90, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (12) This option was canceled in the merger in exchange for a cash payment of \$162,750.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (13) This option was canceled in the merger in exchange for a cash payment of \$894,615.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (14) This option was canceled in the merger in exchange for a cash payment of \$1,584,120.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (15) Each Restricted Stock Unit represents a contingent right to receive one (1) share of Medarex, Inc. common stock.
- (16) This Restricted Stock Unit was canceled in the merger in exchange for a cash payment of \$225,904.00, based on the merger consideration (\$16 per share) pursuant to the merger agreement between issuer and Bristol-Myers Squibb.
- (17) Receipt of the Restricted Stock Units was deferred until February 23, 2010.
- (18)

## Edgar Filing: LONBERG NILS - Form 4

This Restricted Stock Unit was canceled in the merger in exchange for a cash payment of \$516,000.00, based on the merger consideration (\$16 per share) pursuant to the merger agreement between issuer and Bristol-Myers Squibb.

- (19) The Restricted Stock Units vested ratably over four years beginning on April 3, 2009.
- (20) This Restricted Stock Unit was canceled in the merger in exchange for a cash payment of \$688,000 based on the merger consideration (\$16 per share) pursuant to the merger agreement between issuer and Bristol-Myers Squibb.
- (21) The Restricted Stock Units vested ratably over four years beginning on April 5, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.